[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Masaru Matsuda filed a notice to sell 40,638 shares of Arcutis Biotherapeutics common stock through Merrill Lynch on NASDAQ, with an approximate sale date of 02/02/2026. The aggregate market value of the planned sale is 1,027,275 based on the filing data, versus 122,492,192 common shares outstanding.

The shares to be sold were acquired through restricted stock vesting from Arcutis Biotherapeutics on multiple dates, including 02/01/2026, 02/01/2025, 11/18/2024, 11/01/2024, and 08/01/2024, in amounts that total 40,638 shares. In the past three months, Matsuda also sold 1,675 shares on 12/01/2025 for gross proceeds of 50,041 and 2,550 shares on 11/19/2025 for gross proceeds of 72,056.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	40638	1027275	122492192	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			7983	02/01/2026	NA
Common	02/01/2025	Restricted Stock Vesting	Arcutis Biotherapeutics			12648	02/01/2025	NA
Common	11/18/2024	Restricted Stock Vesting	Arcutis Biotherapeutics			4875	11/18/2024	NA
Common	11/01/2024	Restricted Stock Vesting	Arcutis Biotherapeutics			6570	11/01/2024	NA
Common	08/01/2024	Restricted Stock Vesting	Arcutis Biotherapeutics			8562	08/01/2024	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Masaru Matsuda 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	12/01/2025	1675	50041
Masaru Matsuda 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/19/2025	2550	72056

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)